Stock listing

NASDAQ:GNPX Genprex, Inc. Stock

Home listing (NASDAQ) of Genprex, Inc.

Follow Genprex, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GNPX

$1.45 USD -0.26 (-15.2%)

Close on Nov 20, 2026

Past year -97.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.45 – $1.67 USDNov 20, 2026
Volume
93,404 sharesNov 20, 2026
Market cap
$1.94M USDAt the close on Nov 20, 2026 · price × 1.33M shares outstanding
52-week range
$1.45 – $80.96 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$476,746 USDMedian day 116,062 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Genprex, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GNPX · Home$1.45 USD-0.26 (-15.2%)93,404$1.64$1.67$1.45$1.71Close on Nov 20, 2026
LSE:0A8I$1.492 USD-0.168 (-10.1%)3,487$1.64$1.80$1.492$1.66Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GNPX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.45-0.26-15.2%$1.64$1.67$1.4593,404
$1.71+0.039+2.4%$1.67$1.85$1.6361,782
$1.671-0.229-12.1%$1.86$1.87$1.66129,654
$1.90-0.18-8.7%$2.01$2.135$1.83116,062
$2.08-0.13-5.9%$2.26$2.26$2.0611,446
$2.21-0.08-3.5%$2.30$2.30$2.2018,816
$2.29+0.20+9.6%$2.11$2.38$2.11158,874
$2.09+0.03+1.5%$2.10$2.20$2.07158,004
$2.06-0.01-0.5%$2.07$2.155$2.0586,305
$2.07-0.03-1.4%$2.11$2.13$2.0297,932
$2.10-0.04-1.9%$2.25$2.25$1.95205,889
$2.14-0.17-7.4%$2.35$2.35$2.14244,027
$2.31+0.08+3.6%$2.24$2.38$2.24144,974
$2.23-0.01-0.4%$2.33$2.368$2.159242,573
$2.24+0.20+9.8%$2.02$2.27$2.02164,563
$2.04+0.03+1.5%$1.86$2.10$1.86152,769
$2.01+0.06+3.1%$1.94$2.05$1.85101,826
$1.95+0.14+7.7%$1.86$1.96$1.71109,863
$1.810.000.0%$1.86$1.874$1.79172,372
$1.81-0.17-8.6%$2.08$2.08$1.79212,300
$1.98-0.07-3.4%$1.99$2.05$1.9890,300
$2.05-0.08-3.8%$2.20$2.20$1.91361,600
$2.13+0.07+3.4%$2.07$2.18$2.03234,000
$2.06-0.05-2.4%$2.15$2.215$2.06245,100
$2.11-0.18-7.9%$2.27$2.32$2.10125,500
$2.29-0.04-1.7%$2.30$2.43$2.215224,800
$2.33-0.18-7.2%$2.50$2.55$2.30281,200
$2.51-0.18-6.7%$2.65$2.692$2.51170,803
$2.69-0.03-1.1%$2.88$2.88$2.57283,454
$2.72-0.03-1.1%$2.81$2.93$2.64201,300
$2.75+0.13+5.0%$2.69$2.81$2.659252,400
$2.62+0.01+0.4%$2.62$2.78$2.58227,600
$2.61-0.11-4.0%$2.74$2.75$2.58156,100
$2.72+0.09+3.4%$2.67$2.81$2.61151,700
$2.63+0.07+2.7%$2.56$2.75$2.55118,700
$2.56-0.36-12.3%$2.98$2.98$2.53141,800
$2.92+0.07+2.5%$2.82$3.06$2.76179,300
$2.85+0.04+1.4%$2.82$2.90$2.73101,300
$2.81-0.48-14.6%$3.41$3.41$2.70568,400
$3.29-0.23-6.5%$3.54$3.55$3.26118,800
$3.52-0.23-6.1%$3.66$3.66$3.36244,700
$3.75+0.21+5.9%$3.76$4.20$3.422,488,700
$3.54+0.06+1.7%$3.54$3.60$3.47103,800
$3.48+0.03+0.9%$3.48$3.65$3.46116,800
$3.45-0.01-0.3%$3.45$3.60$3.3757,500
$3.46+0.05+1.5%$3.50$3.58$3.3474,300
$3.41+0.10+3.0%$3.35$3.41$3.2626,800
$3.31-0.14-4.1%$3.45$3.475$3.3025,600
$3.45+0.10+3.0%$3.35$3.569$3.3543,200
$3.350.000.0%$3.39$3.43$3.3327,700
$3.35-0.08-2.3%$3.38$3.44$3.3128,800
$3.43-0.11-3.1%$3.54$3.57$3.36125,900
$3.54+0.04+1.1%$3.47$3.65$3.4228,700
$3.50+0.075+2.2%$3.60$3.605$3.38737,200
$3.425-0.085-2.4%$3.52$3.57$3.3748,400
$3.51-0.04-1.1%$3.51$3.61$3.4940,000
$3.55-0.16-4.3%$3.62$3.64$3.4641,300
$3.71+0.04+1.1%$3.73$3.84$3.6340,700
$3.67+0.06+1.7%$3.68$3.75$3.6355,600
$3.61-0.36-9.1%$3.95$4.02$3.57194,500
$3.97-0.03-0.7%$3.99$4.07$3.9328,000
$4.00-0.02-0.5%$4.02$4.17$3.95171,700
$4.02+0.07+1.8%$4.02$4.12$3.93653,200
$3.950.000.0%$3.90$4.289$3.8696,100
$3.95-0.04-1.0%$3.99$4.05$3.8871,600

Splits

3 splits since 2024 · NASDAQ:GNPX · every price before a split is adjusted for it

DayRatioWhat
1-for-22Consolidation
1-for-50Consolidation
1-for-40Consolidation
Ticker
NASDAQ:GNPX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Genprex, Inc. news

Genprex, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 130 in all · newest Nov 19, 2026 · oldest 2019
Decks
28 decks · latest Jul 14, 2026

Where Genprex, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GNPX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:GNPXBOATSUnited StatesUSD
Frankfurt:2DEFrankfurtGermanyEUR
LSE:0A8ILSEUnited KingdomUSD
gettex:2DEgettexGermanyEUR
Munich:2DEMunichGermanyEUR

Valuation

Price/book 0.1× against a median of 0.5×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$13.41M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.08

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Genprex, Inc. · NASDAQ:GNPXUS$1.94M−US$13.41Mn/an/an/a0.1×n/a0.0×1.08
Medicus Pharma Ltd. · NASDAQ:MDCXUS$2.18M−US$2.73Mn/an/an/an/an/an/a2.03
Senti Biosciences Holdings, Inc. · NASDAQ:SNTIUS$2.06M−US$3.49Mn/a−47.2×n/an/an/an/a2.91
CASI Pharmaceuticals, Inc. · OTC:CASIFUS$2.06MUS$38.79Mn/a1.9×n/an/a−218.6%n/a-0.07
Vectus Biosystems Limited · ASX:VBSUS$2.02MUS$50,9461.9×n/an/a1.3×n/a0.2×n/a
Decoy Therapeutics Inc. · NASDAQ:DCOYUS$1.98M−US$6.19Mn/a−11.6×n/a0.4×n/a0.0×1.28
Propanc Biopharma, Inc. · NASDAQ:PPCBUS$1.84MUS$1.62Mn/an/an/a0.3×n/a0.0×1.39
Argent Biopharma Ltd · ASX:RGTUS$1.79MUS$8.05Mn/a75.4×n/an/an/an/an/a
Calidi Biotherapeutics, Inc. · AMEX:CLDIUS$1.76M−US$2.19Mn/an/an/a1.1×n/a0.0×1.86
Kala Bio, Inc. · NASDAQ:KALAUS$1.74M−US$5.49Mn/an/an/a0.2×n/a0.0×2.76
SOHM, Inc. · OTC:SHMNUS$1.74MUS$4.99Mn/a5.5×n/a0.5×−28.1%0.9×-0.10
Median of the othersUS$1.91M−US$1.07M1.9×1.9×0.5×−123.3%0.0×1.63

Forecasts

Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
7.50 USD · Analysts' mean
EPS, year to Dec 2024
-4.25 · 1 analyst

Team and board

Officers

OfficerRole
Ryan M. ConferPresident, Chief Executive Officer, Chief Financial Officer
Kate CombsVice President of Clinical Operations
Celina LaneyChief of Staff
Greg JancarikSenior Director and Corporate Controller
Kalyn DabbsDirector of Communications
Tracy HuynhAccounting Manager

Board

DirectorRole
Jose A. Moreno ToscanoBoard Chairman
Brent LongneckerBoard Director
William WilsonBoard Director

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026−14.0%
Q2 2026Aug 14, 2026−8.1%
Q1 2026Jun 3, 2026−5.4%
Q4 2025Mar 27, 2026−5.8%
Q3 2025Nov 14, 2025−2.4%
Q2 2025Aug 14, 2025−5.8%
Q1 2025Apr 1, 2025 · Before open−6.1%
Q4 2024Mar 31, 2025 · After close−6.1%
Q3 2024Nov 13, 2024 · Before open−23.4%
Q2 2024Aug 9, 2024 · After close−11.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close−3.4%
Q4 2023Feb 26, 2024 · After close−4.8%
Q3 2023Nov 14, 2023 · After close+10.6%
Q2 2023Aug 21, 2023 · After close+8.0%
Q1 2023May 22, 2023 · After close−0.3%
Q4 2022Mar 31, 2023 · After close−3.3%
Q3 2022Nov 14, 2022 · Before open+2.2%
Q2 2022Aug 12, 2022 · After close+18.1%
Q1 2022May 13, 2022 · After close−0.7%
Q4 2021Mar 30, 2022 · After close−1.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck66 slidesJul 14, 2026
Investor Presentation (April 2026)Investor deck64 slidesApr 21, 2026
Investor Presentation (January 2026)Investor deck64 slidesJan 7, 2026
Investor Presentation (October 2025)Investor deck62 slidesOct 17, 2025
Investor Presentation (January 2025)Investor deck61 slidesJan 13, 2025
Investor Presentation (June 2024)Investor deck57 slidesJune 2024
Investor Presentation (February 2024)Investor deck54 slidesFebruary 2024
Investor Presentation (January 2024)Investor deck52 slidesJan 5, 2024
Investor Presentation (September 2023)Investor deck52 slidesSep 8, 2023
Investor Presentation (January 2023)Investor deck49 slidesJan 6, 2023
All 28 decks
DeckKindSlidesDate
Investor Presentation (November 2022)Investor deck45 slidesNov 21, 2022
Investor Presentation (October 2022)Investor deck44 slidesOct 21, 2022
Investor Presentation (October 2022)Investor deck39 slidesOct 11, 2022
Investor Presentation (April 2022)Investor deck50 slidesApr 27, 2022
Investor Presentation (January 2022)Investor deck50 slidesJan 3, 2022
Investor Presentation (January 2022)Investor deck49 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck49 slidesNov 17, 2021
Investor Presentation (July 2021)Investor deck48 slidesJul 12, 2021
Investor Presentation (May 2021)Investor deck48 slidesMay 13, 2021
Investor Presentation (March 2021)Investor deck35 slidesMar 2, 2021
Investor Presentation (March 2021)Investor deck46 slidesMarch 2021
Investor Presentation (November 2020)Investor deck34 slidesNov 16, 2020
Investor Presentation (September 2020)Investor deck34 slidesSeptember 2020
Investor Presentation (August 2020)Investor deck32 slidesAug 3, 2020
Investor Presentation (February 2020)Investor deck23 slidesFeb 5, 2020
Investor Presentation (January 2020)Investor deck22 slidesJan 9, 2020
Investor Presentation (August 2019)Investor deck20 slidesAug 30, 2019
IPO Roadshow (September 2017)IPO roadshow21 slidesSep 15, 2017

Open Decks

Financings

RaiseDate
Registered direct offering of shares of common stock, with unregistered short-term warrants
Announced: about US$3.4M · US$9 a share · Warrants at US$8.75 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Oct 28, 2025
Registered direct offering of shares of common stock, with unregistered short-term warrants
Announced: about US$2.7M · US$11.21 a share · Warrants at US$11 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Oct 23, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a share on Oct 13, 2017.

Price
US$5.00 a share

Steps

StepWhen
Draft sent to the SEC in confidenceJun 5, 2017
Filed publiclyJul 21, 2017
Amended 6 timesNewest Oct 10, 2017
Shares registered with an exchangeOct 13, 2017
Declared effective by the SECOct 13, 2017
Final prospectus, with the priceOct 13, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Oct 13, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue6.69K15.0K25.6K22.5K22.8K13.1K000
Gross profit-6.69K-15.0K-25.6K-22.5K-22.8K-13.1K000
Research and development9.43M10.5M17.6M11.5M8.97M7.30M1.97M971.4K289.9K354.9K
Selling, general and administrative6.09M10.6B13.4M12.3M11.0M10.6M11.4M11.4M3.02M3.78M
Operating income-15.5M-21.2M-31.1M-23.8M-20.7M-18.0M-10.7M-12.4M-3.31M-4.13M
Depreciation and amortization06.69K15.0K25.6K22.5K22.8K13.1K5.88K3.24K862
EBITDA-15.5M-21.2M-31.0M-23.8M-20.6M-17.9M-10.7M-12.4M-3.31M-4.13M
Interest expense739.9K018.1M5.13K038.0K38.0K1.89K0
Income before tax-16.2M-21.1M-30.9M-23.7M-20.7M-17.9M-10.7M-12.4M-3.31M-4.13M
Income tax02.65K00-5.13K-18.8K29.2K29.2K800
Net income-16.2M-21.1M-30.9M-23.7M-20.7M-17.9M-10.7M-12.4M-3.31M-4.13M
Earnings per share, basic-17.40-266.89-22.56-19.80-0.44-0.51-0.66-0.90-0.29-0.38
Earnings per share, diluted-0.42-0.51-0.66-0.90-0.29-0.38

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.83M1.60M6.74M21.0M38.6M27.3M2.00M8.60M161.3K1.60M
Short-term investments1.60B0
Receivables034.9K01276559.30K8.84K8.18K
Inventory3.01M801.8K0
Current assets8.36M2.08M7.53M21.5M39.1M27.7M2.98M8.85M193.6K1.64M
Property, plant and equipment007.86K23.0K48.6K39.4K44.7K24.4K7.80K5.16K
Goodwill0
Total assets10.2M4.12M10.7M25.1M42.9M31.4M3.53M9.27M1.26M1.91M
Accounts payable743.1K1.07M1.40M442.9K973.2K193.0K436.3K295.1K629.1K109.7K
Current liabilities2.17M2.50M3.25M2.81M1.59M450.7K510.7K387.8K831.0K285.7K
Long-term debt0
Total debt92.8K92.8K201.9K
Total liabilities2.20M2.50M3.25M2.81M1.59M450.7K510.7K387.8K831.0K285.7K
Shareholders' equity7.96M1.62M7.42M22.3M41.3M30.9M3.02M8.88M428.6K1.62M
Shares outstanding149.8K217.2K1.49M1.20M47.9M43.1M19.3M15.2M11.7M11.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-15.3M-17.9M-24.7M-17.6M-14.3M-13.9M-6.92M-6.85M-2.17M-1.25M
Capital spending-10-71.4K0-31.7K-17.6K-33.4K-22.4K-5.89K-4.98K
Free cash flow-15.3M-17.1M-24.8M-17.6M-14.3M-14.0M-6.95M-6.87M-2.18M-1.25M
Cash from investing0774.6K-71.2K-59.7K-83.8K-2.34M-946.9K-103.3K-63.4K-89.5K
Cash from financing21.5M12.0M10.6M6.43K25.7M41.6M1.27M15.4M794.0K2.71M
Dividends paid-277.1M0
Share buybacks41.6M1.27M15.4M794.0K2.71M
Change in cash6.23M-5.14M-14.2M-17.7M11.3M25.3M-6.60M8.44M-1.44M1.37M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026Current reportSEC
8-K · Current reportNov 4, 2026Current reportSEC
8-K · Current reportOct 28, 2026Current reportSEC
8-K · Current reportOct 21, 2026Current reportSEC
8-K · Current reportAug 18, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026Current reportSEC
8-K · Current reportAug 3, 2026Current reportSEC
8-K · Current reportJul 30, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJul 14, 2026Current reportSEC
S-8 · Registration statement for employee plansJun 26, 2026Offer documentSEC
8-K · Current reportJun 22, 2026Current reportSEC
8-K · Current reportJun 18, 2026Management or board changeSEC
8-K · Current reportJun 12, 2026Current reportSEC
S-3 · Registration statementJun 5, 2026Offer documentSEC
8-K · Current reportMay 26, 2026Current reportSEC
8-K · Current reportMay 14, 2026Current reportSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 11, 2026Big-stake noticeSEC
8-K · Current reportApr 30, 2026Current reportSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
8-K · Current reportApr 28, 2026Current reportSEC
8-K · Current reportApr 21, 2026Current reportSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 18, 2026Current reportSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
8-K · Current reportFeb 23, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
8-K · Current reportFeb 10, 2026Current reportSEC
8-K · Current reportJan 9, 2026Current reportSEC
S-8 · Registration statement for employee plansJan 9, 2026Offer documentSEC
8-K · Current reportJan 7, 2026Current reportSEC
8-K · Current reportJan 6, 2026Current reportSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
8-K · Current reportDec 23, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 15, 2025Other filingsSEC
424B3 · ProspectusDec 12, 2025Offer documentSEC
CORRESP · Letter to the SECDec 10, 2025Other filingsSEC
S-1/A · Registration statement, amendedNov 26, 2025Offer documentSEC
8-K · Current reportNov 26, 2025Current reportSEC
S-1 · Registration statementNov 21, 2025Offer documentSEC
8-K · Current reportNov 21, 2025Current reportSEC
424B5 · ProspectusNov 21, 2025Offer documentSEC
8-K · Current reportNov 19, 2025Current reportSEC
8-K · Current reportNov 18, 2025Current reportSEC
S-8 · Registration statement for employee plansNov 14, 2025Offer documentSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
424B5 · ProspectusNov 10, 2025Offer documentSEC
8-K · Current reportNov 4, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 3, 2025Big-stake noticeSEC
8-K · Current reportOct 29, 2025Material contractSEC
424B5 · ProspectusOct 29, 2025Offer documentSEC
8-K · Current reportOct 28, 2025Current reportSEC
8-K · Current reportOct 24, 2025Material contractSEC
424B5 · ProspectusOct 24, 2025Offer documentSEC
8-K · Current reportOct 23, 2025Current reportSEC
8-K · Current reportOct 21, 2025Current reportSEC
8-K · Current reportOct 17, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveSep 17, 2025Other filingsSEC
424B3 · ProspectusSep 16, 2025Offer documentSEC
CORRESP · Letter to the SECSep 12, 2025Other filingsSEC
S-1 · Registration statementSep 12, 2025Offer documentSEC
UPLOAD · Letter from the SECSep 11, 2025Other filingsSEC
DRS · Draft registration statementSep 5, 2025Offer documentSEC
8-K · Current reportAug 20, 2025Current reportSEC
8-K · Current reportAug 18, 2025Current reportSEC
8-K · Current reportAug 15, 2025Management or board changeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
RW · Request to withdraw a registrationAug 5, 2025Other filingsSEC
DEFA14A · Additional proxy materialAug 4, 2025Meeting noticeSEC
8-K · Current reportAug 4, 2025Current reportSEC
ARS · Annual report to shareholdersJul 16, 2025Annual reportSEC
DEF 14A · Proxy statementJul 16, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 3, 2025Meeting noticeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJun 24, 2025Current reportSEC
8-K · Current reportJun 23, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJun 18, 2025Other filingsSEC
424B3 · ProspectusJun 17, 2025Offer documentSEC
CORRESP · Letter to the SECJun 16, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 16, 2025Other filingsSEC
S-1 · Registration statementJun 11, 2025Offer documentSEC
8-K · Current reportJun 11, 2025Material contractSEC
8-K · Current reportJun 9, 2025Current reportSEC
S-1 · Registration statementMay 14, 2025Offer documentSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025Current reportSEC
8-K · Current reportMay 6, 2025Current reportSEC
8-K · Current reportApr 28, 2025Current reportSEC
DRS · Draft registration statementApr 24, 2025Offer documentSEC
NT 10-K · Late filing noticeApr 1, 2025Explanation requestSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
8-K · Current reportFeb 18, 2025Material contractSEC
8-K · Current reportFeb 12, 2025Current reportSEC
S-8 · Registration statement for employee plansJan 24, 2025Offer documentSEC
8-K · Current reportJan 23, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 15, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
424B5 · ProspectusDec 20, 2024Offer documentSEC
8-K · Current reportDec 16, 2024Current reportSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
8-K · Current reportNov 20, 2024Current reportSEC
8-K · Current reportNov 19, 2024Current reportSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
424B5 · ProspectusNov 8, 2024Offer documentSEC
8-K · Current reportNov 5, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 24, 2024Big-stake noticeSEC
8-K · Current reportOct 24, 2024Current reportSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
8-K · Current reportOct 15, 2024Current reportSEC
SC 13G · Big-stake noticeOct 3, 2024Big-stake noticeSEC
8-K · Current reportSep 26, 2024Current reportSEC
8-K · Current reportSep 4, 2024Current reportSEC
424B5 · ProspectusAug 16, 2024Offer documentSEC
8-K · Current reportAug 13, 2024Current reportSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportJun 27, 2024Current reportSEC
8-K · Current reportJun 24, 2024Management or board changeSEC
424B5 · ProspectusMay 20, 2024Offer documentSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024Management or board changeSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansApr 17, 2024Offer documentSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
424B5 · ProspectusMar 20, 2024Offer documentSEC
8-K · Current reportMar 20, 2024Material contractSEC
8-K · Current reportMar 6, 2024Current reportSEC
8-K · Current reportFeb 26, 2024Current reportSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 5, 2024Management or board changeSEC
8-K · Current reportFeb 2, 2024Management or board changeSEC
8-K · Current reportJan 31, 2024Current reportSEC
8-K · Current reportJan 5, 2024Current reportSEC
8-K · Current reportDec 18, 2023Meeting outcomeSEC
424B5 · ProspectusDec 13, 2023Offer documentSEC
8-K · Current reportDec 13, 2023Material contractSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
DEFA14A · Additional proxy materialNov 3, 2023Meeting noticeSEC
DEF 14A · Proxy statementNov 3, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 23, 2023Meeting noticeSEC
8-K · Current reportOct 23, 2023Current reportSEC
8-K · Current reportSep 25, 2023Current reportSEC
8-K · Current reportSep 8, 2023Current reportSEC
8-K · Current reportSep 1, 2023Current reportSEC
8-K/A · Current report, amendedAug 21, 2023Current reportSEC
10-Q · Quarterly reportAug 21, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeAug 15, 2023Explanation requestSEC
SC 13G · Big-stake noticeJul 24, 2023Big-stake noticeSEC
424B5 · ProspectusJul 20, 2023Offer documentSEC
8-K · Current reportJul 19, 2023Material contractSEC
8-K · Current reportJul 18, 2023Material contractSEC
8-K · Current reportJul 14, 2023Current reportSEC
4 · Change in ownershipJun 29, 2023Insider tradeSEC
4 · Change in ownershipJun 29, 2023Insider tradeSEC
4 · Change in ownershipJun 29, 2023Insider tradeSEC
8-K · Current reportJun 27, 2023Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveJun 12, 2023Other filingsSEC
CORRESP · Letter to the SECJun 7, 2023Other filingsSEC
8-K · Current reportMay 26, 2023Current reportSEC
10-Q · Quarterly reportMay 22, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeMay 16, 2023Explanation requestSEC
8-K/A · Current report, amendedMay 12, 2023Current reportSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
UPLOAD · Letter from the SECApr 27, 2023Other filingsSEC
8-K/A · Current report, amendedApr 27, 2023Current reportSEC
4 · Change in ownershipApr 24, 2023Insider tradeSEC
4 · Change in ownershipApr 24, 2023Insider tradeSEC
S-3 · Registration statementApr 21, 2023Offer documentSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 13, 2023Current reportSEC
8-K · Current reportMar 6, 2023Current reportSEC
424B5 · ProspectusFeb 28, 2023Offer documentSEC
8-K · Current reportFeb 27, 2023Material contractSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC

This page holds 200 of 492 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Genprex, Inc.’s releases · as of Nov 9, 2026

Common shares
1,334,753
Fully diluted
1,334,753

Fully diluted

LineSharesAs of
Common shares1,334,753Nov 9, 2026

Share count over time

CountShares
Nov 9, 20261,334,753

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund25,1191.9%US$19,580May 31, 2026
Vanguard Extended Market Index Fund5,9500.45%US$3,088Jun 30, 2026
Fidelity Series Total Market Index Fund1,5220.11%US$1,186May 31, 2026
Fidelity Total Market Index Fund6850.05%US$534May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Longnecker Brent M
Director
Sale8USD 1.23US$10Apr 14, 2026
Longnecker Brent M
Director
Sale10USD 1.23US$12Apr 14, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Catherine M Vaczy
Other companies: Lisata Therapeutics, Inc. (General Counsel · Oct 31, 2008 – Apr 13, 2015 · Past)
EVP GC Chief Strategy Officer · Mar 12, 2020 – Apr 21, 2023 · Past
Mark Stanley Berger
Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Chief Medical Officer · Mar 16, 2017 – Sep 1, 2021 · Past)
Chief Medical Officer · Since at least Sep 27, 2021
Brent LongneckerDirector · Since at least Apr 14, 2026
Celina LaneyChief of Staff · Since at least Nov 5, 2026
Greg JancarikSenior Director and Corporate Controller · Since at least Nov 4, 2026
Hermant KumarChief Mfgr & Tech Officer · Sep 27, 2021 – Feb 18, 2023 · Past
John Rodney VarnerChairman, President and CEO, Director · Mar 28, 2018 – Feb 18, 2024 · Past
Jose A. Moreno ToscanoBoard Chairman · Since at least Nov 5, 2026
Kalyn DabbsDirector of Communications · Since at least Oct 28, 2026
Kate CombsVice President of Clinical Operations · Since at least Nov 4, 2026
All 14 people
PersonSeat
Robert W PearsonDirector · Mar 28, 2018 – Dec 30, 2019 · Past
Ryan M. ConferPresident, Chief Executive Officer, Chief Financial Officer · Since at least Jul 28, 2022
Tracy HuynhAccounting Manager · Since at least Nov 5, 2026
William WilsonBoard Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Genprex, Inc.